Zarbin MA, Hill L, Maunz A, et al. - In this post hoc HARBOR trial analysis, researchers intended to determine if there is an association between subretinal fluid (SRF), macular atrophy (MA) and visual outcomes in ranibizumab-treated neovascular age-related macular degeneration (nAMD). This investigation involved ranibizumab-treated (0.5 or 2.0 mg, monthly or as-needed, all treatment arms pooled) eyes with nAMD and baseline (screening, baseline and week 1) SRF. Seven hundred and eighty-five eyes out of a total of 1,097 met the criteria for analysis. TR-SRF (treatment-resistant subretinal fluid) had no effect on vision outcomes after 2 years, regardless of thickness. MA rates were significantly higher in the absence of TR-SRF.